These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 10919199)

  • 1. [The use of biological markers in the diagnosis and follow-up of patients with multiple sclerosis. Test of five fluids].
    Oehninger-Gatti C; Buzó R; Alcántara JC; Chouza C; Gómez A; Cibils D; Gordon-Firing S
    Rev Neurol; 2000 May 16-31; 30(10):977-9. PubMed ID: 10919199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients.
    Lebrun C; Bensa C; Debouverie M; Wiertlevski S; Brassat D; de Seze J; Rumbach L; Pelletier J; Labauge P; Brochet B; Tourbah A; Clavelou P;
    Arch Neurol; 2009 Jul; 66(7):841-6. PubMed ID: 19597085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
    Chowdhury SA; Lin J; Sadiq SA
    Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness.
    Link H; Huang YM
    J Neuroimmunol; 2006 Nov; 180(1-2):17-28. PubMed ID: 16945427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of evoked potential examinations in patients with clinically isolated optic neuritis in light of the revised McDonald criteria.
    Simó M; Barsi P; Arányi Z
    Mult Scler; 2008 May; 14(4):472-8. PubMed ID: 18208873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis.
    Zipoli V; Hakiki B; Portaccio E; Lolli F; Siracusa G; Giannini M; Pantoni L; Pescini F; Sorbi S; Amato MP
    Mult Scler; 2009 Apr; 15(4):472-8. PubMed ID: 19153171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis with uncommon cerebrospinal fluid findings.
    Rot U; Mesec A; Pogacnik T
    Croat Med J; 2003 Dec; 44(6):697-701. PubMed ID: 14652881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological diagnostic criteria in multiple sclerosis].
    Dimitri D
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):968-73. PubMed ID: 11787362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Findings of cerebrospinal fluid in the diagnosis of multiple sclerosis].
    Drulović J; Stojsavljević N; Dujmović I; Sokić D; Mavra M; Lević Z
    Srp Arh Celok Lek; 1995; 123(7-8):191-3. PubMed ID: 17974427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early differential diagnosis of multiple sclerosis using a new oligoclonal band test.
    Villar LM; Masjuan J; Sádaba MC; González-Porqué P; Plaza J; Bootello A; Alvarez-Cermeño JC
    Arch Neurol; 2005 Apr; 62(4):574-7. PubMed ID: 15824255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid.
    Arneth B; Birklein F
    Acta Neurol Scand; 2009 Jan; 119(1):39-44. PubMed ID: 18573131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis.
    Rinker JR; Trinkaus K; Cross AH
    Neurology; 2006 Oct; 67(7):1288-90. PubMed ID: 17030770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence.
    Boster A; Caon C; Perumal J; Hreha S; Zabad R; Zak I; Tselis A; Lisak R; Khan O
    Mult Scler; 2008 Jul; 14(6):804-8. PubMed ID: 18573830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis.
    Villar LM; García-Barragán N; Sádaba MC; Espiño M; Gómez-Rial J; Martínez-San Millán J; González-Porqué P; Alvarez-Cermeño JC
    J Neurol Sci; 2008 Mar; 266(1-2):34-7. PubMed ID: 17884100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
    Tintoré M; Rovira A; Río J; Tur C; Pelayo R; Nos C; Téllez N; Perkal H; Comabella M; Sastre-Garriga J; Montalban X
    Neurology; 2008 Mar; 70(13 Pt 2):1079-83. PubMed ID: 17881717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability.
    Prat A; Biernacki K; Saroli T; Orav JE; Guttmann CR; Weiner HL; Khoury SJ; Antel JP
    Arch Neurol; 2005 May; 62(5):795-800. PubMed ID: 15883268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of VEP assessment and immunological csf analysis in the diagnosis of childhood and juvenile MS].
    Zgorzalewicz M; Michałowska-Wender G; Losy J; Wender M
    Przegl Lek; 2003; 60 Suppl 1():1-4. PubMed ID: 12945153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, magnetic resonance imaging, cerebrospinal fluid and electrophysiological characteristics of the earliest multiple sclerosis.
    Rot U; Ledinek AH; Jazbec SS
    Clin Neurol Neurosurg; 2008 Mar; 110(3):233-8. PubMed ID: 18093725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will Rogers phenomenon in multiple sclerosis.
    Sormani MP; Tintorè M; Rovaris M; Rovira A; Vidal X; Bruzzi P; Filippi M; Montalban X
    Ann Neurol; 2008 Oct; 64(4):428-33. PubMed ID: 18688811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of MRI in patients with multiple sclerosis].
    Tourbah A
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1124-7. PubMed ID: 11787344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.